Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)

China flag China · Delayed Price · Currency is CNY
12.02
-0.16 (-1.31%)
Mar 11, 2026, 10:25 AM CST
23.41%
Market Cap 3.77B
Revenue (ttm) 874.60M
Net Income (ttm) -190.75M
Shares Out 309.54M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend 0.20 (1.67%)
Ex-Dividend Date May 29, 2025
Volume 1,372,700
Average Volume 2,972,946
Open 12.18
Previous Close 12.18
Day's Range 12.00 - 12.20
52-Week Range 9.40 - 18.18
Beta 0.61
RSI 49.40
Earnings Date Apr 28, 2026

About SHE:002900

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate... [Read more]

Sector Healthcare
Founded 1996
Employees 2,522
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002900
Full Company Profile

Financial Performance

In 2024, SHE:002900's revenue was 1.13 billion, a decrease of -4.58% compared to the previous year's 1.19 billion. Earnings were 58.68 million, a decrease of -20.35%.

Financial Statements

News

There is no news available yet.